drugset
drugset / Trial / NCT01797874

Pazopanib Maintenance for SCLC

NCT01797874 ↗

Phase 2 Completed 97 enrolled Samsung Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Timeline

Start
2013-06
Primary completion
2017-02
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule — —

Indications

small cell lung carcinoma